Myriad Genetics beat estimated earnings by 180.0%, reporting an EPS of $0.04 versus an estimate of $-0.05. Revenue was down $800 thousand from the same period last year. In the previous quarter, the ...
StockStory.org on MSN
Myriad Genetics's (NASDAQ:MYGN) Q4 CY2025 sales top estimates, stock jumps 22%
Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported in Q4 CY2025, but sales were flat year on year at $209.8 million. The company expects the full year’s revenue to be around $870 million, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results